Skip to content

Choroidal Blood Flow Changes During Dark/Light Transitions in Patients With Insulin-dependent Diabetes Mellitus (IDDM)

Choroidal Blood Flow Changes During Dark/Light Transitions in Patients With IDDM

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00718614
Enrollment
80
Registered
2008-07-18
Start date
2007-06-30
Completion date
2007-07-31
Last updated
2014-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1, Diabetic Retinopathy

Keywords

Choroidal blood flow, Laser Doppler flowmetry, Diabetic Retinopathy, Diabetic Neuropathy

Brief summary

There is evidence from a variety of animal studies that choroidal blood flow is under neural control. Recent results in humans indicate that a light/dark transition is associated with a short lasting reduction in choroidal blood flow. Several observations indicate that the changes in choroidal perfusion are triggered at least in part by neural mechanisms. Particularly, we have shown that during unilateral dark/light transition both eyes react with choroidal vasoconstriction strongly indicating a neural mechanism for blood flow regulation. Investigation of changes in choroidal blood flow during light/dark transition may represent an interesting approach to study neural dysregulation at the level of the eye in patients with IDDM. Accordingly, the hypothesis of reduced choroidal blood flow responses to a light/dark transition in patient with IDDM will be tested. This response in choroidal blood flow will be correlated to parameters of diabetic neuropathy and diabetic retinopathy.

Interventions

PROCEDURELight will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.

Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

For healthy control subjects: * Men and women aged over 18 years, matched in regard to age, sex and smoking status * Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant * Normal ophthalmic findings, Ametropia \< 3 dpt for healthy control subjects For patients with IDDM: * Men and women aged over 18 years * Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * Long standing IDDM \> 10 years * Mild or moderate to severe non-proliferative diabetic retinopathy (defined according to the MAHC) * Ametropia \< 3 dpt

Exclusion criteria

Any of the following will exclude a healthy subject from the study: * Regular use of vasoactive medication with may interfere with the study procedure, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study * Symptoms of a clinically relevant illness in the 3 weeks before the first study day * Blood donation during the previous 3 weeks Any of the following will exclude a patient with IDDM from the study: * Evidence of any relevant retinal or choroidal disease (Glaucoma, age related macula degeneration, cataract, history of central retinal artery obstruction or central retinal vein thrombosis) * Ophthalmological surgery (history of photo laser coagulation, including argon laser trabeculoplasty (ALT), trabeculectomy, deep sclerectomy) * History of intravitreal injection with anti-proliferative therapy * Need for dialysis * Non-treated systemic hypertension (SPB\>150, DBP\>95) * Evidence of coronary heart disease, cardiomyopathy, stenocardia, congestive heart failure, peripheral occlusive vascular disease, cardiac autonomic neuropathy * Symptoms of a clinically relevant illness in the 3 weeks before the first study day * Blood donation during the previous 3 weeks

Design outcomes

Primary

MeasureTime frame
fundus pulsation amplitude3 hours
choroidal blood flow3 hours

Secondary

MeasureTime frame
Nerve conduction velocitymeasured before intervention
Pupil diameter during infra-red pupillometrymeasured before intervention
heart rate variabilitymeasured before intervention

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026